News & Updates

Treatment with vixarelimab yields clinically meaningful improvements in prurigo nodularis (PN) symptoms, while having a favourable safety profile, according to a phase 2b study.

The oral, selective factor D inhibitor vemircopan falls short of meeting the prespecified threshold for efficacy in the treatment of generalized myasthenia gravis, as shown in a phase 2 trial.

A phase 2a trial of rheumatoid arthritis (RA) has shown no significant difference between the investigational branebrutinib and placebo in terms of clinical efficacy, despite the drug having a favourable safety profile.

Treatment with sacituzumab tirumotecan (sac-TMT) significantly improves progression-free survival (PFS) and overall survival (OS) in patients with previously treated advanced EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) compared with docetaxel, according to the OptiTROP-Lung03 study presented at ELCC 2026.

Users of semaglutide do not appear to be at greater risk of developing nonarteritic anterior ischaemic optic neuropathy (NAION), suggests a study.

The investigational benzamide LB-102 (N-methyl amisulpride) is well tolerated and helps reduce symptoms in patients with schizophrenia experiencing an acute episode, according to the results of the NOVA1 phase 2 trial.

A secondary analysis of the phase III CAPTAIN-1st trial shows a significant overall survival (OS) benefit when camrelizumab is added to gemcitabine and cisplatin (GC) for the first-line (1L) treatment of recurrent or metastatic nasopharyngeal carcinoma (RM-NPC).

Individuals with overweight or obesity in East Asia shed more weight following treatment with the fixed-dose combination of cagrilintide plus semaglutide than with semaglutide alone, as shown in the phase 3a REDEFINE 5 trial.